Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan's Lap-Band AP approved in Europe for diabetes

This article was originally published in The Gray Sheet

Executive Summary

Adjustable gastric banding system for obesity intervention becomes the first such device to gain European market approval for weight loss that leads to improvement or remission of type 2 diabetes, the firm announces June 26. The approval was supported by results of a two-year randomized trial that confirmed results from previous observational studies. The study showed that patients who lost weight with Lap-Band AP were over five-times more likely to achieve remission of type 2 diabetes than patients receiving conventional diabetes therapy (73% vs. 13%). Expanded labeling for the device states that weight loss associated with the system "has been shown to improve or lead to remission of type 2 diabetes," the company says
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT027617

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel